UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1946 - 1960
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Induction Chemotherapy | Male | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Ustekinumab - pharmacokinetics | Crohn Disease - drug therapy | Ustekinumab - immunology | Adult | Female | Maintenance Chemotherapy | Infusions, Intravenous | Intravenous administration | Cytokines | Body weight | Clinical trials | Interleukin 23 | Interleukin 12 | Antagonists | Patients | Crohns disease | Side effects | Tumor necrosis factor | Immunotherapy | Monoclonal antibodies | Tumor necrosis factor-TNF | Remission | Index Medicus | Abridged Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 05/2017, Volume 76, Issue 5, pp. 831 - 839
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Severity of Illness Index | Double-Blind Method | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Antirheumatic Agents - immunology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Monoclonal - therapeutic use | Male | Methotrexate - therapeutic use | Ustekinumab - therapeutic use | Retreatment | Ustekinumab - pharmacokinetics | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | Treatment Failure | Ustekinumab - immunology | Adult | Antirheumatic Agents - pharmacokinetics | Female | Aged | Ustekinumab - administration & dosage | Antibodies, Monoclonal - immunology | Antirheumatic Agents - therapeutic use | Treatment outcome | Care and treatment | Rheumatoid arthritis | Analysis | Dosage and administration | Research | Methotrexate | Index Medicus | Disease Activity | Clinical and Epidemiological Research | Treatment | Rheumatoid Arthritis | 1506
Journal Article
Inflammatory bowel diseases, ISSN 1078-0998, 06/2016, Volume 22, Issue 7, pp. 1662 - 1669
refractory | Crohn's disease | ustekinumab | IL-12 | IL-23 | inflammatory bowel disease | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Drug Administration Schedule | Follow-Up Studies | Rectal Fistula - etiology | Humans | Middle Aged | Male | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Crohn Disease - complications | Spain | Cutaneous Fistula - drug therapy | Cutaneous Fistula - etiology | Retreatment | Anti-Inflammatory Agents - adverse effects | Crohn Disease - drug therapy | Injections, Subcutaneous | Rectal Fistula - drug therapy | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Retrospective Studies | Ustekinumab - administration & dosage | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2019, Volume 381, Issue 13, pp. 1201 - 1214
ACTIVITY INDEXES | INFECTIONS | EFFICACY | INFLIXIMAB | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Humans | Induction Chemotherapy | Male | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Dose-Response Relationship, Drug | Patient Acuity | Anti-Inflammatory Agents - adverse effects | Injections, Subcutaneous | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Remission Induction - methods | Maintenance Chemotherapy | Colitis, Ulcerative - drug therapy | Infusions, Intravenous | Ustekinumab - administration & dosage | Treatment outcome | Drug therapy | Analysis | Ulcerative colitis | Intravenous administration | Cytokines | Research & development--R&D | Body weight | Interleukin 23 | Interleukin 12 | Hemorrhage | Testicular cancer | Esophagus | Inflammatory bowel disease | Respiratory distress syndrome | Gastroenterology | Rectum | Tumor necrosis factor-TNF | Remission | Colon | Endoscopy | Prostate cancer | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
The Lancet (British edition), ISSN 0140-6736, 08/2018, Volume 392, Issue 10148, pp. 650 - 661
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumor Necrosis Factor-alpha - metabolism | Dermatologic Agents - administration & dosage | Humans | Middle Aged | Ustekinumab - pharmacology | Antibodies, Monoclonal - adverse effects | Male | Dermatologic Agents - adverse effects | Interleukin-23 Subunit p19 - metabolism | Injections, Subcutaneous - methods | Placebos | Adult | Female | Interleukin-23 Subunit p19 - drug effects | Ustekinumab - administration & dosage | Dermatologic Agents - pharmacology | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Immunoglobulin G - therapeutic use | Treatment Outcome | Interleukin-12 - metabolism | Psoriasis - ethnology | Ustekinumab - adverse effects | Antibodies, Monoclonal - administration & dosage | Clinical trials | Analysis | Interleukin | Immunoglobulin G | Interleukin 23 | Infections | Evidence-based medicine | Skin cancer | Randomization | Motivation | Gangrene | Tumor necrosis factor-TNF | Safety | Active control | Effectiveness | Psoriasis | Cytokines | Adjustment | Melanoma | Patients | Weight | Quality of life | Studies | Tuberculosis | Tumor necrosis factor | Monoclonal antibodies | TNF inhibitors | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
JAMA dermatology (Chicago, Ill.), ISSN 2168-6068, 04/2017, Volume 153, Issue 4, pp. 304 - 308
Life Sciences & Biomedicine | Dermatology | Science & Technology | Up-Regulation | Follow-Up Studies | Humans | Ustekinumab - pharmacology | Male | Treatment Outcome | Dermatologic Agents - therapeutic use | RNA, Messenger - metabolism | Ustekinumab - therapeutic use | Interleukin-23 - genetics | Pityriasis Rubra Pilaris - genetics | Psoriasis - pathology | Th17 Cells - metabolism | Time Factors | Biopsy | Pityriasis Rubra Pilaris - drug therapy | Adult | Cytokines - genetics | Pityriasis Rubra Pilaris - pathology | Dermatologic Agents - pharmacology
Journal Article
Journal of autoimmunity, ISSN 0896-8411, 2017, Volume 82, pp. 41 - 46
Allergy and Immunology | Ustekinumab | Vasculitis | Oral ulcer | Biotherapy | Behçet disease | Life Sciences & Biomedicine | Immunology | Science & Technology | Prospective Studies | Follow-Up Studies | Humans | Symptom Assessment | Behcet Syndrome - drug therapy | Male | Treatment Outcome | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Oral Ulcer - drug therapy | Biomarkers | Adult | Female | Behcet Syndrome - diagnosis | Disease Management | Behcet Syndrome - metabolism | Ustekinumab - administration & dosage | Behcet Syndrome - immunology | Medicine, Experimental | Medical research | Antiulcer drugs | Index Medicus
Journal Article
Clinical gastroenterology and hepatology, ISSN 1542-3565, 09/2017, Volume 15, Issue 9, pp. 1427 - 1434.e2
Inflammatory Bowel Disease | Therapeutic Drug Monitoring | Biologic | UNITI | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Prospective Studies | Humans | Middle Aged | Ustekinumab - pharmacology | Child, Preschool | Male | Young Adult | Immunologic Factors - pharmacokinetics | Colonoscopy | Injections, Subcutaneous | Aged, 80 and over | Adult | Female | Ustekinumab - administration & dosage | Child | Cross-Sectional Studies | Biomarkers - analysis | Immunologic Factors - administration & dosage | Treatment Outcome | Ustekinumab - pharmacokinetics | Crohn Disease - pathology | Crohn Disease - drug therapy | Adolescent | Aged | Longitudinal Studies | Immunologic Factors - pharmacology | Viral antibodies | Antibodies | Medical colleges | Biological products | Interleukins | Care and treatment | C-reactive protein | Gastrointestinal diseases | Patient outcomes | Index Medicus
Journal Article
Arthritis care & research (2010), ISSN 2151-464X, 12/2015, Volume 67, Issue 12, pp. 1739 - 1749
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Disability Evaluation | Severity of Illness Index | Double-Blind Method | Joints - drug effects | Europe | Humans | Inflammation Mediators - blood | Treatment Outcome | Biomarkers - blood | North America | Remission Induction | Ustekinumab - therapeutic use | Ustekinumab - adverse effects | Cross-Over Studies | C-Reactive Protein - metabolism | Time Factors | Ustekinumab - pharmacokinetics | Arthritis, Psoriatic - blood | Arthrography | Arthritis, Psoriatic - diagnostic imaging | Arthritis, Psoriatic - drug therapy | Index Medicus | Psoriatic Arthritis
Journal Article